Introduction
Escherichia coli (E. coli) took the highest position in causative gram-negative bacterium from bloodstream infection (BSIs) patients in Asia region [1] . It led to severe infections with a high rate of shock and mortality [2] . Currently, the worldwide incidence of E. coli BSI is still increasing over time [3] with the overall incidence increased year on year [4] that suggested an increasing burden of disease [5] . The estimation of infections worldwide showed that thirdgeneration cephalosporin-resistant E. coli and K. pneumoniae caused 6.4 million (interval estimate 3.5-9.2) BSIs and 50.1 million (27.5-72.8) serious infections in 2014 [6] . In addition, it was difficult to treat because of the emergence of multi-drug resistance (MDR) of E. coli [7] . Thus, evaluating antibiotic susceptibility is essential to decide what types of antibiotics and what appropriate doses that improving treatment efficiency and minimizing the antibiotic resistance rate. Over 20 years, the susceptibility of E. Coli BSIs was alarmed with the prevalence of antimicrobial-resistant isolates was increased [8] . In these cases, the patients had a worse prognosis with partial effect on correct empirical treatment [9] . Antimicrobial resistance-related encoding gene in each E. coli strain. Extended-spectrum β-lactamases https://www.id-press.eu/mjms/index (ESBLs) was one of the most important genes [10] . It minimized the antibiotic efficiency in treatment [11] . Besides, the ability of inter-transmission within different E. Coli strains and transmission between E. Coli and other bacteria led to the state of becoming widespread resistance genes around the world. It becomes public-health concern [12] with increasing burden and cost of hospital-acquired infections [13] , [14] .
In Vietnam, there was one study in Northern Vietnam showed 25.1% of ESBLs among Enterobacteriaceae causing BSIs [15] 
Materials and Methods
The cross-sectional study was done in the period from 12/2012 to 6/2014 in two tertiary hospitals in Northern Vietnam (National Hospital of Tropical Diseases and 103 Military Hospital). Isolating from hospitalized BSIs patients in two hospitals 56 E. coli strains were inoculated in BHI Broth with 20% glycerol after being identified at the labs of these two hospitals. Using QIAamp DNA Mini Kit (USA) for DNA extraction (including isolation and quantification), we performed the experimental procedure according to manufacturer's instruction. PCR amplification performed in PCR master mix (Invitrogen -USA) that consisted of 200 µM of each dNTPs (dATP, dCTP, dGTP, dTTP), 100 pM primers, 1 U Taq DNA polymerase, 10 mM Tris-HCl, 50 mM KCl, 1,5 mM MgCl 2 and 10 µl DNA template. Specific primers for bla TEM , bla SHV , bla CTX-M , bla PER genes showed in Table  1 . The experiments were performed using the protocol with 30 cycles that each of them consisted of 3 steps including denaturing (95°C for 30 seconds), annealing (58, 57, 60, 54°C for 30 seconds), elongating (72°C for 1 minute). PCR products were performed electrophoresis, imaged routinely and sequenced. The sequence of PCR products was compared with the original gene's sequence on GenBank to confirm bla TEM , bla SHV , bla CTX-M and bla PER gene. 
Statistical Analysis
The statistical analysis was conducted using the R language [17] . Graphics also were performed by R language (version 3.5.2). The analysis of such enormous volumes of information in the acquisition of data from 56 strains, each strain companion with subtype genes (three bla TEM subtypes, four bla CTX-M subtypes, eight bla SHV subtypes) and 15 
Results
Clinical characteristics of the patient in this study showed in Table 2 . Among 56 E. coli strains isolated analyzed, 39.3% strains were identified as producing ESBL. Detail information of sequencing results showed in Table 3 highlighting three bla TEM subtypes (bla TEM The results of gene analysis revealed that 100% of isolates harbored bla TEM gene, but none of them had the bla PER gene ( Table 4 ). The prevalence of bla CTX-M gene of overall strains, ESBL-producing, and non-ESBL-producing were 76.79%, 81.8%, and 73.5%, respectively. The prevalence of bla SHV gene among ESBL-producing and non-ESBL-producing strains were 18.2% and 35.3%. More information showed in Table 4 . Figure 2 showed highly active antibiotics such as doripenem (DOR-96.4% of strains), ertapenem (ETP-94.6% of strains), amikacin (AK-96.4% of strains), and cefepime (PEP-89.3% of strains). In each antibiotic, detail information of genes was shown. Figure 3 showed that in patients who carried gene had high rate of antibiotic resistance with the main antibiotics were ceftazidime (3-CAZ), cefazolin (6-CZ), doripenem (7-DOR), gentamycin (10-GM), levofloxacin (11-LVX), ampicillin/sulbactam (12-SAM), trimethoprim/sulfamethoxazole (13-SXT) in line with bla CTX-M gene with the same allocation. Tobramycin (14-TM) with intermediate response had bla SHV and bla TEM as main genes. Figure 3 Table 5 clarified the detail of antibiotic resistance with the ESBL gene. While ESBL-positive strains were highly resistant to ampicillin (AM), ceftriaxone (CRO), cephazolin (CZ), and trimethoprim/sulfamethoxazole (SXT) at the rate of 100%, 100%, 100%, and 81.8%, respectively, ESBLnegative strains had a lower prevalence of resistance to these agents at the rate of 76.5%, 11.8%, 17.7%, and 53%, respectively. Both groups were susceptible to doripenem (DOR), ertapenem (ETP), and amikacin (AK) at the rate of more than 90%. 
Figure 2: Antibiotic sensitivity profile; Antibiotics are 1 to 15 following 15 antibiotic have been coded Amikacin (1-AK); Ampicillin (2-AM); Ceftazidime (3-CAZ); Ciprofloxacin (4-CIP); Ceftriaxone (5-CRO); Cefazolin (6-CZ); Doripenem (7-DOR); Ertapenem (8-ETP); Cefepime (9-FEP); Gentamycin (10-GM); Levofloxacin (11-LVX); Ampicillin/Sulbactam (12-SAM); Trimethoprim/sulfamethoxazole (13-SXT); Tobramycin (14-TM); Piperacillin/Tazobactam (15-TZP)

to 5 following CTX-M gene, ESBL gene, PER gene, SHV gene and TEM gene; Anti -biotic RSI is 1 to 3 following R (resistance), S (sensitive), I (intermediate); Antibiotics are 1 to 15 following 15 antibiotic have been coded Amikacin (1-AK), Ampicillin (2-AM), Ceftazidime (3-CAZ), Ciprofloxacin (4-CIP), Ceftriaxone (5-CRO), Cefazolin (6-CZ), Doripenem (7-DOR), Ertapenem (8-ETP), Cefepime (9-FEP), Gentamycin (10-GM), Levofloxacin (11-LVX),
Discussion
ESBL-producing E. coli is common genotypes and its incidence varies from region to region. ESBLs are typically inhibitor-susceptible B-lactamases that are encoded by mobile genes with the bla CTX-M , bla SHV , and bla TEM families were the most frequently. In our study, among 56 E. coli strains have been analyzed, 39.3% strains were identified as ESBL-producing. Our finding is higher than that of study in Northern, Vietnam (25.1% of strains produced ESBL among Enterobacteriaceae) [15] . Comparing with other countries, it is higher than Singapore (33%) [18] , Chile (23.8%) and Brazil (12.8%) but lower than that of India (60%), Hong Kong (48%) [18] Mexico (48.4%) [19] . All cases with ESBL-producing E. Coli had bla TEM gene and the 100% resistance to ampicillin was found that in line with the present study [20] .
Our results about bla CTX-M gene also corroborated another study that reported bla CTX-M bla (beta-lactamase) gene was common in all the ESBL isolates [21] . This result is also in agreement with study Gurntke et al., of that among 19% ESBLpositive cases, bla CTX-M -15 was the most common genotypes (60%), followed by bla SHV -5 (27%) [22] . Other studies showed the same results with bla CTX-M -14 (48% of the isolates) were the most frequent ESBL [11], [23] . It was observed that the predominant of subtypes bla CTX-M gene was diverse from study to study. Analyzing 552 isolates from BSIs that resistance to third-generation cephalosporin showed more detail with bla CTX-M -15 (50%), bla CTX-M -14 (14%), bla CTX-M -27 (11%) and bla CTX-M -101 (5%) [24] .
ESBL-producing E. Coli in BSIs have been shown a substantial increase in the 21 st century [25] . Besides that, its burden was growing worldwide [26] . Finding the appropriate therapy became crucial and carbapenems emerged as 'best therapy' for ESBLproducing bacteria [25] . But in the time of antibiotics and resistance becoming popular, E. Coli also starts resistance to carbapenem that leading a high financial burden and increased mortality [27] .
The knowledge of antibiotic resistance profile is key in clinical practice. The high rate of resistance to some routine antibiotic agents which were commonly used in most hospitals in our area was provided in this study. The results also showed that amikacin and carbapenems (doripenem and ertapenem) emerged as choices for empiric therapy instead. Sinha et al., showed similar findings with high prevalence of ESBL-positive, high rate of resistance to ampicillin (86%), ceftriaxone (80.6%), and fluoroquinolones (80%) and the clear choice for empirical treatment were carbapenems in these cases [21] .
Knowing the risk factors of antibiotic resistance is crucial for management strategy. The time before hospitalization was an only independent risk factor among ESBL in BSIs [28] while previous use of oxyimino-beta-lactams was the only modifiable risk factor among nosocomial BSIs [11] . In our study, ESBL encoding genes showed high correlation with antibiotic resistance.
While ESBL-positive strains were highly resistant to ampicillin, ceftriaxone, cephazolin, and trimethoprim/sulfamethoxazole at the rate of 100%, 100%, 100%, and 81.8%, respectively, ESBL-negative strains showed a lower prevalence of resistance to these agents at the rate of 76.5%, 11.8%, 17.7%, and 53%, respectively. Both groups were susceptible to doripenem, ertapenem, and amikacin at the rate of more than 90%. This finding was similar to the study in Finland from 1999 to 2013 that showed most (88%) of the isolates reported as non-susceptible to thirdgeneration cephalosporins had ESBL phenotype [29] .
In conclusion, in Escherichia coli causing bloodstream infections, antibiotic resistance was higher in ampicillin, trimethoprim/sulfamethoxazole and cephazolin Antibiotics was highly susceptible including doripenem, ertapenem, amikacin, and cefepime.
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